Top

Author Archive |

Marieke Van der Pluijm, University of Amsterdam

Marieke Van der Pluijm image

Treatment resistance in schizophrenia is a major clinical problem with one third of schizophrenia patients showing non-response to standard antipsychotic treatment. The delay in identifying these patients leads to prolonged ineffective treatment, longer hospitalization, unnecessary side effects and lower quality of life for those individuals. There is an urgent need for (bio)markers that can identify treatment-resistant patients early on, enabling timely intervention and improving prognosis.

During my PhD I have developed a keen interest in the neurobiology of psychosis and its relation to treatment response in first episode psychosis. Elucidating the underlying neurobiology of treatment resistance in psychosis could aid in better treatment selection and result in markers for earlier identification of these patients. The core focus of my PhD was the development and application of the novel neuromelanin-sensitive MRI (NM-MRI) technique as a potential clinical marker for treatment resistance. Additionally, I explored alternative markers, including plasma dopa decarboxylase activity as a blood marker and alterations in neurotransmitters, including glutamate and gamma-aminobutyric acid (GABA) levels. These markers hold significance for guiding treatment decisions, particularly in considering clozapine, the antipsychotic recognized for its superior effectiveness in treatment resistant schizophrenia.

At the SIRS 2022 conference, I had the honor to receive an early career award and to present the most notable finding from my PhD including a NM-MRI study in first episode psychosis patients. NM-MRI is a novel non-invasive MRI technique that indirectly measures dopamine functioning. In psychosis research, a common method for evaluating dopamine functioning is [18F]F-DOPA PET imaging, which has consistently shown increased activity in specific brain areas. Interestingly, treatment resistant patients do not show this increased dopamine functioning and show levels comparable to healthy individuals. Unfortunately, [18F]FDOPA PET imaging is expensive and relatively burdensome for patients, since it uses radioactivity and is administered intravenously, making it impractical for widespread use in screening for treatment resistance. NM-MRI as a proxy of dopamine functioning presents a promising alternative due to its non-invasive nature. NM-MRI shows increased signal in schizophrenia patients compared to healthy individuals, but had not yet been tested in treatment resistant schizophrenia. We aimed to determine whether treatment resistant patients show lower NM-MRI signal compared to patients who responded to antipsychotic medication. To accomplish this, we conducted a study in first episode psychosis patients, with a baseline and 6 month follow up measurement. In line with our hypothesis, treatment resistant patients showed significantly lower NM-MRI signal compared to responders, and similar NM-MRI signal compared to healthy individuals. Furthermore, NM-MRI appeared to be relatively robust as NM-MRI signal remained stable over six months follow-up and was not associated with illness duration, medication duration or dosage. These findings provide further evidence for dopaminergic differences between treatment resistant patients and responders, and support the potential of NM-MRI as a clinically applicable marker for treatment resistance in schizophrenia. This study has recently been published in the American Journal of Psychiatry and can be accessed online.

Following our findings that treatment resistant schizophrenia may be associated with a normal dopamine rather than an increased dopamine system, we redirected our attention to another neurotransmitter system: glutamate and GABA. These neurotransmitters are believed to play a role in treatment resistant schizophrenia. As a result, we aimed to further elucidate the roles of glutamate and GABA in the anterior cingulate cortex in first episode treatment resistant schizophrenia. I will present the results of this study as a poster at SIRS 2024 on Thursday.

Currently, I am a post-doctoral researcher at the Department of Psychiatry, Amsterdam UMC in the Netherlands. In this role I contribute to various projects, encompassing both neuroimaging and clinical studies in psychosis. Moving forward, I plan to expand my research endeavors while continuing to lend my expertise to other projects. Over the coming years, my goal is to deepen my understanding and experience in the field of psychosis. Eventually I want to use my accumulated expertise to pursue grants and establish my own research program dedicated to improving diagnostics and treatment for early psychosis.

Jakob Kaminski, Charité University Medical Center Berlin

Jakob Kaminski Image

My first contact with brain research was already in school in biology classes. The complex biology of the brain functioning was fascinating to me because of it’s many mysteries. When deciding what to study I always wanted to do research but also wanted to work on something that is directly related to people’s lives. The challenges in medicine seemed to fit these requirements. During my first internships I was intrigued by psychiatry and schizophrenia research. There were so many open questions and riddles to solve. So I started to do brain research at the Max-Planck Institute for Cognitive and Brain Sciences in Leipzig and then started my clinical career at Charité Berlin focusing on brain research in Schizophrenia. During my clinical routine I was fascinated by the extraordinary powers and abilities patients have. Although behavior sometimes is described as "non-functional" there is an enormous creativity and resilience in people with mental disorders. The multifactorial origins of those disorders have long puzzled researchers and clinicians alike. It’s multifaceted nature presents a significant challenge, but also an opportunity for innovation and discovery.

When I started my career, I embarked on a journey to unravel the intricacies of schizophrenia. I started with cutting-edge imaging technology and the goal for better understanding the human brain during crisisNeuroimaging techniques have revolutionized our ability to explore the complexities of the brain. Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), and Functional MRI (fMRI) allow us to visualize the structure, function, and connectivity of neural circuits with unprecedented detail. These tools offer invaluable insights into the pathophysiology. I focused on alterations in glutamatergic and dopaminergic brain functioning, however, I was not completely satisfied and felt that despite decades of research, the underlying neurobiological mechanisms remain elusive, making diagnosis and treatment such a challenging task. I then delve more into the complex interaction of environmental factors and psychotic experiences. And landed in digital health to support patients in outpatient setting with innovative and effective tools. In addition to advancing our understanding of schizophrenia, technology has also revolutionized the way we support and empower patients. Digital tools and mobile applications have emerged as valuable adjuncts to traditional therapeutic approaches. These tools offer a wide range of functionalities, including symptom tracking, medication management, activation of resources and psychoeducation. One of the most significant advantages of digital tools is their ability to tailor interventions to the individual needs of patients. While the integration of digital tools into schizophrenia care holds immense promise, it is not without its challenges. Issues such as data privacy, accessibility, and the digital divide must be carefully addressed to ensure equitable access to these resources. Additionally, ongoing research is needed to validate the efficacy of these interventions and optimize their usability in clinical settings. In conclusion, the intersection of neuroimaging research and digital technology offers unprecedented opportunities to advance our understanding of schizophrenia and transform patient care. By embracing innovation and collaboration, we can navigate the challenges ahead and continue to support and empower patients during their recovery. While working in the field of schizophrenia research fostering interdisciplinary collaboration is what I enjoyed the most. 

Katherine Grace Jonas, Stony Brook University

Katherine Grace Jonas

I began studying genetics in my first year at Harvard, somewhat by accident. I had applied to be part of a seminar entitled “Chess and Mathematics,” but that course was filled, and I was bumped into “Darwin’s Finches”. I was disappointed, but not for long. I began to spend time in the archives of the Museum of Natural History, measuring the beaks of finches collected nearly 200 years ago, each with a tag tied to its leg with minute handwriting denoting the bird’s scientific name. Holding the birds that inspired the theory of evolution was the start of my fascination with genetics and classification. The next semester I moved to a synthetic biology wet lab, and after that to a drosophila lab at the Fred Hutchinson Cancer Research Center. At the same time, I was developing an interest in psychiatry and clinical psychology. My grandfather, who I idolized, was a psychiatrist. His son, who I never met, was diagnosed with schizophrenia. The family was unusually tight-knit, so my uncle’s absence was conspicuous, and highlighted how profoundly schizophrenia had impacted my father’s family of origin.  

I pursued a doctorate in clinical psychology at the University of Iowa because it presented the opportunity to pursue genomics research and clinical training in psychopathology. At both Iowa and the Minneapolis Veterans Affairs Medical Center, I was able to spend time with individuals who had experienced psychosis, working on inpatient, partial hospitalization, and outpatient treatment settings. When a postdoctoral opportunity arose on the Suffolk County Project, led by Drs. Roman Kotov and Evelyn Bromet and currently the longest-running study of first-admission psychosis in the world, I was thrilled to merge my research and clinical interests. My work with the project has focused on understanding how genetic risk factors manifest longitudinally over the 35 years the study has been running. We have shown that genetic risk can indicate who is more likely to experience a more severe course of negative symptoms. With the leaders of other first-episode studies, we are developing a consortium of longitudinal studies that can definitively evaluate how genetic risk impacts the course of symptoms, cognition, function, and response to treatment in psychotic disorders. 

In the past two years, I have developed an arm of research that aims to leverage what we know about the structure of psychosis to improve the power and precision of psychosis GWAS. Preliminary results from these analyses have confirmed the genetic structure of psychotic symptoms, mania, and depressive symptoms mirrors phenotypic structure, such that each genetic factor is relatively independent of the other. The support of the SIRS Early Career Award allowed me to present this work at the society’s 2022 meeting. A related line of research takes a broader approach, and tests whether transdiagnostic phenotypes of internalizing, externalizing, and psychosis, can identify more genetic risk factors than case-control GWAS. My hope is that this line of research will provide a clearer picture of psychotic disorders and the genetic risk factors associated with them, to facilitate the development of better diagnostic tools and treatments. 

Leandro Valiengo, University of Sao Paulo

Leandro Valiengo, University of Sao Paulo

We are excited to share that the SIRS 2020 Research Fund Awardee, Leandro Valiengo, has agreed to a SIRS Q&A. View our questions and his answers below!

What were you able to achieve with the SIRS Research Fund Award? 

The negative symptoms of schizophrenia are very hard to treat and very disabling. If photobiomodulation is demonstrated to be effective in future clinical trials, then it may help patients and their families to cope with the disease and improve their life quality.

How has your work shaped today's ongoing research?  

Today we are focusing on expanding the results of this pilot assessment by developing new clinical trials with new variables and more patients..

How has your work made an impact on patient's lives? 

The negative symptoms of schizophrenia are very hard to treat and very disabling. Giving them an option of treatment with favorable results, helps them and their families to cope with the disease and improves their life quality.

What is your ultimate goal in research? 

Now I want to explore the benefits of this technique (and maybe other types of noninvasive neuromodulation) in other symptoms of schizophrenia. My main objective is to improve the quality of life of patients with schizophrenia (and other severe mental disorders) through new treatments that have fewer side effects. I also intend to keep mentoring graduation and post-graduation students to initiate or expand their research skills.

What made you decide to pursue research into psychosis/schizophrenia? 

Treatment resistance in Schizophrenia is very common. This condition inputs a high rate of disability, and the negative symptoms are challenging to treat and limit the quality of life of the patients. So, the search for new treatments in this area, especially concerning the negative symptoms of the disorder, was imperative.

What made you pursue these specific research methods (i.e. genetics, neuroimaging, postmortem, etc.)?

I used brain photobiomodulation because there were other studies using this technique for Alzheimer's disease with promising results. My hypothesis was that if we used the same technique to stimulate the prefrontal cortex, known to be dysregulated in the negative symptoms of schizophrenia, the patients would have an improvement in symptom control.

 What researcher/scientist (doesn't have to be a SIRS member) has influenced your work the most and how?  

My mentor is Prof. Andre Brunoni, from the University of Sao Paulo, Brazil, who studies the use of neuromodulation techniques for humor disorders. He has a brief but extremely productive research career, with some impressive results, and has already published in highly prestigious periods, like NEJM and Lancet.

 

The Research Fund Award program is intended to provide research funds for junior investigators who have an important idea or hypothesis to test, but are lacking in research funds to do so. You can find out more by clicking here.

Parsa Ravanfar, University of Melbourne

Parsa Ravanfar, University of Melbourne

I am a medical graduate and PhD candidate in neuropsychiatry, aiming to pursue a career in clinical psychiatry and neuroscience. During my clinical training, I learned about the large impact of schizophrenia on the individual and community, which attracted me to the research of schizophrenia. I am impressed by the complex phenomenology of psychosis and how little we still know about it. In my research, I am particularly passionate about the biological underpinnings of psychiatric illnesses, including schizophrenia. I believe that by understanding the cellular- and network-level brain mechanisms that are associated with schizophrenia, we will be able to develop more effective treatment modalities to fill the gaps in our current therapeutic options. Advanced neuroimaging modalities allow us to study the brain in individuals with schizophrenia in real time, providing a unique opportunity to understand the brain as it functions. My PhD research focuses specifically on imaging of iron content in the brain in schizophrenia. Iron is closely linked to dopaminergic neurotransmission, one of the main neurotransmitter systems implicated in schizophrenia. At SIRS 2022, I presented the findings of our group that describes higher content of iron in specific brain regions accompanied by network wide alterations of iron distribution in people with schizophrenia. Excess iron leads to neural damage by generating oxidative stress. Therefore, it is possible that this iron accumulation could be associated with the structural brain changes and cognitive decline that are observed in individuals with schizophrenia. By attending SIRS 2022, I was able to present my study to research groups from around the world and learn about their scientific discoveries relevant to my work. This helped me reshape my research ideas and deepen my understanding of several pathologic cellular processes other than oxidative stress that are associated with iron burden. I met leaders in the field with whom I am hoping to collaborate to uncover more of the unknowns about biological processes in schizophrenia.

As my future direction, I am aiming to continue using advanced neuroimaging tools to understand brain changes in psychiatric illnesses with a primary focus on schizophrenia. Pending further studies and expanding our knowledge about oxidative stress and iron in schizophrenia, we can think about new therapeutic options to mitigate oxidative stress or reduce iron content in the brain, which could potentially alleviate the brain changes and symptoms of schizophrenia.

The Early Career Award program is intended to sponsor individuals who have, through their research, teaching or clinical activities, demonstrated a professional and scientific interest in the field of schizophrenia research. You can find out more by clicking here.

Cecilie K. Lemvigh, Copenhagen University Hospital

Cecilie K. Lemvigh, Copenhagen University Hospital

My interest in schizophrenia began already as a young university student and was motivated by a growing curiosity of how the human mind works. I am particularly interested in the developmental perspective on cognitive and brain maturation to examine trajectories leading to psychopathology. Currently, a precise understanding of the abnormal processes resulting in psychosis is lacking. I strongly believe that a better understanding of complex developmental trajectories may help progress the field in terms of more effective prevention programs, improved diagnosis, and individualised treatment strategies.

My presentation at the 2022 SIRS Annual Congress focused on this issue by examining how the combination of multiple early risk factors such as parental history of psychosis, low birth weight, premature birth, winter/spring birth, urbanicity, immigration status, paternal age, maternal smoking during pregnancy, and Apgar scores influence the age of illness onset in children, adolescents, and adults with psychosis. We conducted a nationwide register study of all individuals in Denmark receiving a schizophrenia spectrum diagnosis from 1973-2018 (N≈30.000) and a healthy control sample (N≈140.000). Here we found that parental history of psychosis, advanced paternal age, maternal smoking and low birth weight independently increased the risk of a schizophrenia spectrum disorder. Subgroup analyses based on sex revealed that advanced paternal age only increased the risk in females. Approximately 20% of the patients could be characterized as child-onset cases (<18 years) with female sex and parental history of psychosis as significant predictors of having an early onset. We also observed a cumulative effect of the early risk factors on age of illness onset with more risk exposures resulting in an earlier age of onset. These findings provide a basis for future treatment strategies in terms of individual risk stratification and early intervention, which from a health policy perspective is necessary in order to prevent, delay or attenuate the impact of schizophrenia spectrum disorders.

In ongoing studies, we relate the register data to our clinical cohorts and explore how these early risk factors influence cognitive performance at the time of illness onset. A better understanding of how multiple early risk factors acting in combination influence neurodevelopment may shed light on the mechanism underlying cognitive deficits in schizophrenia.

The inclusion of register data limits the effect of recall bias when examining exposures occurring many years prior to illness onset. The combination of clinical and register data is highly unique worldwide and will hopefully contribute with valuable knowledge to the field of psychosis.

Participating in SIRS 2022 and receiving the honour of an early career award was highly beneficial to further broaden my current knowledge and expertise, expand my international network, exchanging ideas and establishing new collaborations.

Finally, although we already know a lot about the development of the brain, we still have a lot to learn regarding the abnormal processes leading to cognitive impairments and emerging psychopathology. Much more research is needed to develop more effective treatments and improve the life of our patients. In this regard, I would like to express my deepest gratitude and appreciation towards all the patients in our studies for putting research before their own suffering, sharing a piece of their story and enduring long hours of psychiatric evaluation and neuropsychological testing.

The Early Career Award program is intended to sponsor individuals who have, through their research, teaching or clinical activities, demonstrated a professional and scientific interest in the field of schizophrenia research. You can find out more by clicking here.

Maria Fransisca Alonso Sanchez, Western University

Maria Fransisca Alonso Sanchez, Western University

One of the factors that has inspired me to work in psychosis and schizophrenia research is the challenge to improve the functional impairment of persons with schizophrenia and the current therapeutic approaches available. As a speech and language pathologist (SLP) I have a particular interest in the functionality, quality of life, and social inclusion of people, and as a researcher, I know that we must put efforts into generating evidence-based therapeutic mechanisms that help us to address these issues.  

In this context, my work so far has focused on finding meaningful patterns in the speech of people with schizophrenia and how the words they use relate to each other. Specifically, we observed that people within their first episode of psychosis used more words that are synonyms or are very similar to each other throughout their discourse, i.e., they had more inefficient discourse. This is a fundamental feature at the level of communication, but we went further and wanted to understand how these patterns relate to other cognitive domains, in particular interference control. Interference control is a cognitive function that allows us to select relevant information from irrelevant information for a particular context. Indeed, we observed that aberrant word selection is correlated with interference control. We then conducted a 6-month follow-up in a section of our sample and observed that neither speech inefficiency nor negative symptoms improved with pharmacological treatment. Finally, with an emphasis on unraveling how these patterns are associated with certain brain areas of the language network, we performed an analysis of resting-state effective connectivity with functional MRI in people with first episode of schizophrenia. We observed that there are two areas of great interest that are modulated by ineffective speech, i.e., these areas could be involved in this phenomenon and therefore could be possible targets for stimulation or treatment. These topics have been a priority for me as they have potential use in the implementation of language intervention programs in combination with brain neuromodulation for people with schizophrenia. There is still a lot of work to be done to understand the relationship between language and the brain language network.  

I believe it will be a significant and rewarding challenge for future researchers from translational cognitive neuroscience to incorporate this new knowledge and improve quality of life for people experiencing schizophrenia. This new knowledge can also be utilized to generate evidence-based intervention programs that are effective and efficient. Finally, I would like to remark that as an SLP we have another challenge, which is to be part of the mental health team to implement these interventions. However, this is not automatic and we need more people who specialize in the area because working with people with aphasia or dementia is not the same as working with persons with schizophrenia. I firmly believe that if we work on evidence-based programs and specialization in mental health, SLPs can provide a great contribution to the intervention and treatment process for people with schizophrenia.  

The Early Career Award program is intended to sponsor individuals who have, through their research, teaching or clinical activities, demonstrated a professional and scientific interest in the field of schizophrenia research. You can find out more by clicking here.

Teresa Vargas, Northwestern University

Teresa Vargas, Northwestern University

Psychotic disorders are complex, debilitating, and not very well understood. Symptoms are often debilitating, and the gaps in care are astonishing. Psychosis and severe mental illness take a toll on both an individual, and societal level. Though we experience the world on an individual level, structural, societal, and cultural features permeate everything that we do. In other words, our physical and social environments shape our every experience. Though our brains have evolved to be sensitive to the environments we inhabit, the degree of sensitivity varies by developmental stage and interacts with individual factors in ways that we do not yet fully understand. My research focuses on understanding the complex back and forth between individuals and their environments to inform prevention and intervention efforts to reduce risk for psychosis and severe mental illness.

My work so far, as a result, has aimed to understand psychosis vulnerability from both an individual and systemic lens.  Specifically, my first line of research aims to relate environmental exposures directly to vulnerability for developing a psychotic disorder. While individual-level environmental factors such as supportive parenting and childhood trauma have been extensively studied, local, regional, and country-level factors are relatively less understood within clinical science. Given that systemic inequities and environmental factors are not well understood, in a recent study I sought to establish distinct dimensions of types of structural environmental exposures. These included stimulation exposures conferring lack of safety and high attentional demands (e.g., neighborhood crime and population density), deprivation exposures constituting a lack of developmentally appropriate resources (e.g., neighborhood deprivation), and discrepancy exposures conferring feelings of social exclusion and lack of belonging (e.g., neighborhood income inequality and low ethnic density). I found evidence that these types of exposures could be meaningfully conceptualized as distinct (Vargas et al., 2021). Of note, all environmental exposure domains (measured by both objective measures such as Census-derived neighborhood characteristics, and self-report) related to psychosis vulnerability, with some exposures (e.g., deprivation) showing stronger associations relative to others. This work suggests that going beyond individual-level exposures, toward neighborhood, societal, and even cultural features, could be highly informative for psychosis vulnerability and resilience models.

My second line of research aims to dig further by identifying candidate neural and functional mechanisms through which environmental factors impact mental health across development. I have used MRI methods because I believe by allowing us a window into what is going on in our brains structurally, they allow us to understand possible lasting impacts of stress, environments, and systemic inequities. Interestingly, MRI allows us to identify relations between the brain, stress, and environments across different ages, which could help us understand how development plays a role. Particularly, I am interested in how biomarkers of types of environments and links to emergent behavior and health outcomes could aid early identification efforts. Identifying individuals who are most vulnerable to mental illness through environmental disadvantage could ultimately help us intervene earlier. At the population level, it could inform more effective allocation of prevention and intervention resources for vulnerable communities. In a recent study using a nationally representative United States sample of 9-11-year-old children, I found that these stimulation, deprivation, and discrepancy neighborhood-level features were associated with brain regions implicated in a host of cognitive, affective, and social functions (Vargas et al. 2022).  My previous work has shown that these relations hold even after accounting for more proximal, individual-level characteristics such as parental education and household income (Vargas et al., 2020). In my future research, I aim to clarify potential biomarkers and neural features that relate to different environmental factors across different developmental periods.

Understanding the systemic environmental factors that influence mental illness vulnerability is essential to the advancement of prevention and intervention-focused clinical research for vulnerable individuals, psychosis, and severe mental illness. In the future, I hope to apply my work to prevention, intervention, and health disparity-relevant translational research and advocacy. Being a SIRS Early Career Award recipient has been a highly rewarding and enriching experience, where I have had the opportunity to learn from brilliant scientists in the community as to how to achieve these goals in the service of helping individuals with psychosis, harnessing the power of collaboration to build bridges and further understanding.

The Early Career Award program is intended to sponsor individuals who have, through their research, teaching or clinical activities, demonstrated a professional and scientific interest in the field of schizophrenia research. You can find out more by clicking here.

Bobana Samardžija, University of Rijeka

Bobana Samardžija, University of Rijeka

My interest in mental health research spawned from my surroundings - many of my friends and family are living with various mental illnesses, so I became very sensible to these issues from a young age. Every day we are making progress in researching major mental illnesses, but we still do not know how they start or what can be done from early stages to delay its progress. To provide some insight, our lab starts from the very beginning - from cells itself and its proteins. We rely on previous genetic research to identify possible gene candidates and investigate proteins for which they encode and their possible disruption like protein aggregation. Our aims include dissecting proteins to their smallest bits to find which parts could be tipping the scale towards illness progression. Also, we are incorporating environmental factors like stress in our research to provide a bigger picture. My work mostly focuses on depression, which is highly prevalent in patients with schizophrenia, but still not talked about enough. In the future, I hope my work will bring awareness to the connection between schizophrenia (and other psychosis) and depression and how important it is to address both from early stages. On the bigger scale, I also hope research from our lab will provide more insight of specific proteins involved in major mental illnesses, thus leading towards more personalized treatment, but also more sensitive (and earlier) diagnostics. In spirit of this, I would like to emphasize how important conferences like SIRS are to the lives of people with psychosis. As an early career researcher, having an opportunity to learn from leading experts in different fields from across the globe, at one place, means a lot. Attending SIRS 2022 allowed me to meet many senior scientists, even people whose work I have read and relied on heavily in my research. But more importantly, being one of the Early Career Awardee allowed me to talk to my peers about challenges of working in academia and learn about new oportunities to learn outside of the lab.

The Early Career Award program is intended to sponsor individuals who have, through their research, teaching or clinical activities, demonstrated a professional and scientific interest in the field of schizophrenia research. You can find out more by clicking here.

Luciana Diaz-Cutraro, Parc Sanitari Sant Joan de Déu

Luciana Diaz-Cutraro, Parc Sanitari Sant Joan de Déu

Research on schizophrenia: an adventure not to be missed.

After finishing my residency in clinical psychology and training in psychological treatments for severe mental disorders, I decided to go behind the scenes of psychological treatment through research on schizophrenia, and that was the beginning of an incredible adventure!

It was not easy for me to move from clinical psychology to research, it required me to learn new skills from almost zero, until in my last year I started to integrate these two professional profiles. My main motivation for entering the world of psychosis research was to contribute to improving treatments so that as many people with psychosis as possible can have access to them as soon as possible. In addition to this, I discovered that new technologies will be my main interest for the following years of my career.

Undoubtedly, networking, meeting colleagues and references in the field of schizophrenia research is an important part of doing research. In that direction, being able to participate in the 2022 Annual SIRS Congress in Florence, exhibiting my poster in Florence was a unique opportunity to exchange contacts and get invaluable feedback from colleagues. Specifically, this year I presented part of my thesis work at the SIRS 2022 Congress, and it was one of the most enriching experiences of my career! This work explores how jumping to conclusions is related to and can influence how we interpret social information. We found that people with first episodes of psychosis who jump to conclusions are more likely to be impaired in their facial recognition of others' emotions, as well as to attribute the cause of negative events to themselves. However, these same people would not be impaired in decoding what others might be thinking. This new knowledge will allow us to refine psychological treatments that work with information processing biases and shape the topics of therapies toward those directions specifically.

For this work, I had the pleasure of receiving the Early Career Award, which was a unique impulse and a great motivation to continue exploring how to ameliorate the problems that living with psychosis can bring. Thanks to that possibility I was able to share time, exchange ideas and learn with my mentor, Dr. Matcheri Ketshavan. SIRS offers us a unique possibility to meet, exchange and learn from other researchers, both early career and long-time researchers.

How does this adventure continue? Considering the present and, above all, the future of research, I would like to highlight two points of particular interest to me. First, the possibility of developing treatments based on new technologies is a possibility to make them attractive, less expensive and simpler, which is why I am very motivated to continue in this direction after my doctorate. On the other hand, these years I learned that the wonderful thing about working in research lies in the need to generate collaborative work that includes people with psychosis and their families. I consider that first-person knowledge of the problems, as well as the need to generate solutions together, is the most appropriate way to build a research project. I have a lot to learn in this direction and it is very motivating for me. I recommend to colleagues clinical psychologists to enter into the world of schizophrenia research and above all to make community with colleagues through the SIRS. You will not come out the same as you went in!

The Early Career Award program is intended to sponsor individuals who have, through their research, teaching or clinical activities, demonstrated a professional and scientific interest in the field of schizophrenia research. You can find out more by clicking here.

Wordpress Social Share Plugin powered by Ultimatelysocial